Report: Cardiovascular Disease Diagnostics (GIA00195) from ReportBuyer.com

Product Code	GIA00195
Publication Date	March 2008
Publisher	Global Industry Analysts
Product Type	Report
Pages	415

This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in Millions of US$. The major product segments analyzed are In Vitro Diagnostics, and In Vivo Diagnostics. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 72 companies including many key and niche players worldwide such as Abbott Diagnostics, Biosite, Inc., Cambridge Heart, Inc., Cholestech Corp., Dade Behring, Inc., EP Medsystems, GE HealthCare, Liposcience, Inc., Philips Medical Systems, Roche Diagnostics, and Siemens Medical Solutions. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

I. Introduction, Methodology & Product Definitions
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
II. Executive Summary
- 1.Industry Overview
  - Market Analysis
  - Analysis by Product Type
  - Cardiology Diagnostic Imaging: Future Outlook
  - Heart -Facts and Figures
  - Swift Growth in Cardiovascular Disease Devices Market
  - Cardiovascular Diseases Damaging Human Health
  - Mounting Healthcare Costs- "A Real Concern for Economies"
  - Competition in the Cardiac Diagnostics Market
  - Market Trends
  - Advancement of POC Testing Propels Cardiovascular Diagnostics Market
  - Demand on Rise for POC Cardiac Markers
  - Minimal Invasive Procedure Hogs the Limelight of Cardiovascular Treatment
  - Advancements in Alternate-Site Coagulation Monitoring
  - Novel Imaging Techniques Boost in vivo Diagnostic Market
  - Strong Demand for Risk Assessment Markers
  - New Technologies Bring Diagnostics Closer to Patients
  - Trends Cited in the Imaging Technologies Market
  - CT Scanners
  - MRI
  - Move towards Efficient Patient Data Management
- 2.CVD - Cause and Risk Factors
  - CVD - Global Facts
  - Atherosclerosis - Leading Cause for CVD
  - Risk Factors
  - Irreversible Risk Factors
  - Increasing age
  - Sex (gender)
  - Heredity (including Race)
  - Risk Factors that can be controlled
  - Tobacco Smoke
  - High Blood Cholesterol
  - LDL Cholesterol
  - HDL Cholesterol
  - Triglyceride levels
  - Hypercholesterolemia - Conditions Associated with Cholesterol Level
  - High Blood Pressure
  - BP - Leading Cause of Cardiovascular Disease in Young Adults
  - Physical Inactivity
  - Obesity and Overweight
  - Diabetes Mellitus
  - Cardiovascular Disease and Homocysteine Levels
  - Measures for Reducing Cardiovascular Diseases
- 3.Cardiovascular Disease and Conditions
  - Angina Pectoris
  - Arrhythmias
  - Sudden Cardiac Death (SCD)
  - Stroke
  - Congestive Heart Failure
  - Cardiovascular Disease Involving Transplant Patients
- 4.Diagnostic Tests for Cardiovascular Diseases
  - in-Vitro Cardiovascular Diagnostics
  - Cholesterol Testing
  - Use of Markers
  - Creatine Kinase MB
  - Troponin T and Troponin I
  - C-reactive Protein
  - Plasminogen Activator Inhibitor-1
  - D-Dimer
  - Thrombus Precursor Protein
  - Other Cardiac Markers
  - Demand Grows for Risk Assessment Markers
  - A Step Forward in Cardiovascular Risk Assessment
  - in Vivo Diagnostic Tests
  - Computer Imaging / Tomography
  - Electron Beam Computer Tomography (EBCT)
  - Appropriate Conditions for EBCT Diagnosis
  - Cardiac Positron Emission Tomography (PET)
  - Digital Cardiac Angiography/ Digital Subtraction Angiography
  - Magnetic Resonance Imaging (MRI)
  - Single Photon Emission Computed Tomography (SPECT)
  - Echocardiography
  - Different Types of Echo-techniques
  - M-mode (Motion mode, One-dimensional)
  - Two-Dimensional (Cross-sectional)
  - Stress Echocardiogram (Stress Echo)
  - Transesophageal Echocardiogram (TEE)
  - Risks
  - Ultrasound Tests
  - Doppler Ultrasound
  - Intravascular Ultrasound
  - Working
  - Comparative Facts Related to Definitive Diagnosis of Cardiovascular Disease
  - Nuclear Cardiology Tests
  - Applications
  - Types of Nuclear Cardiology Tests
  - Myocardial Perfusion Imaging
  - Applications
  - Risks
  - Ventricular Function Test
  - Types:
  - Testing Cardiac Stress
  - Cardio Vascular Disease Diagnostics Tests in the Pipeline
  - Aderis MRE-0470
  - CardioMEMS Novel Technology
  - Technology Platform
- 5.Product Launches and Developments
  - Philips Rolls out 256-slice CT scanner, Brilliance iCT Scanner
  - Royal Philips Launches Live 3D Transesophageal Echocardiogram Probe
  - GE Healthcare Launches Vivid e Ultrasound Systems
  - Cardionetics Launches ECG Monitor for 24-Hour Real-Time Cardiac Diagnosis
  - Siemens Launches Imaging Release for the ACUSON Sequoia Platform
  - GE Healthcare Launches Version 2.0 of Centricity Cardiology CA1000
  - GE Healthcare Introduces New Capabilities to CardioSoft Diagnostic Software
  - GE Healthcare's Lightspeed VCT Offers Imaging at 70% Lower Exposure
  - Roche Diagnostics Launches cobas h 232 Portable Cardiac Marker System (outside US)
  - Royal Philips Launches New Imaging Tool for Complex Cardiac Arrhythmias
  - Siemens Medical Introduces syngo US, New Echocardiography Solution.
  - Dade Behring Introduces CardioPhase hsCRP Test for Multiple Testing Platforms.
  - Shimadzu Launches Two Models in Angiographic Imaging
  - Omron Healthcare Introduces Non Invasive Vascular Profiling System
  - Abbott Launches XIENCE V, New Coronary Stent System
  - Siemens Medical Introduces Acuson AcuNav 8F, an Advanced Ultrasound Catheter...
  - BioMrieux Introduces High Performance VIDAS Troponin I Ultra
  - Siemens Launches Acuson X300 Ultrasound Platform
  - Siemens Releases Web-Enabled CT
  - GE Introduces Latest Electrocardiograph Device, MAC 3500
  - GE Emphasizes on the Striking Features of New Vivid 7 Dimension '06
  - GE Launches Latest Innova Digital Flat Panel Biplane Imaging Devices
  - Medtronic Introduces Latest Range of Implantable Cardiac Defibrillators
  - Philips Introduces Web Based Cardiac Tools
  - Siemens Showcases Solutions for Cardiac Problems through Molecular Imaging
  - Siemens Presents Advancements in Echocardiography
  - Siemens Debuts syngo BEAT
  - Siemens Combines syngo Dynamics with Soarian for Cardiovascular EPR
  - GE Healthcare Unveils CardIQ Fusion
  - GE Introduces VCT
  - GE Unveils Dynamic VUE
  - GE Launches CardIQ Xpress
  - GE Presents the Ventri for Cardiac Imaging
  - GE Introduces High Definition Magnetic Resonance System
  - Dade Behring Unveils CardioPhase(R) hsCRP Test
  - Siemens Launches Encompass III on C512 Ultrasound Platform
  - Siemens Launches Four New CT Clinical Engines
  - Omron Launches HEM-9000AI Cardiovascular Diagnostic Tool
  - Corgenix Introduces Predictive Cardiovascular Diagnostic Kit, AtherOx
  - Philips Introduces HD11 XE Cardiology Ultrasound System
  - Siemens Introduces Biplane FD Cardiology System
  - Siemens Introduces Syngo Circulation Software for CT Tomography
  - Siemens Introduces SOMATOM Definition for Cardiac Imaging
  - Dade Behring Unveils Homocysteine Test on BN(TM) Systems
  - Roche Unveils Cardiac pro-BNP Test
  - Philips Introduces HD11 XE
  - Corgenix Unveils AtherOx(TM)
  - GE Healthcare Unveils Breakthrough Imaging Technology
  - Philips Launches Products to Detect Heart Problems
  - Philips Unveils Computed Tomography and EP Planning package
  - Philips Widens Magnetic Resonance Kitty
  - New Cardiac Monitoring Products from Philips
  - Siemens Launches Image-Arena
  - Siemens Announces New Procam-Calculator Combined with CT Examination
  - Siemens Medical Solutions Launches Axiom Artis dTA
  - GE Healthcare Unveils Vivid i
  - GE Healthcare Presents Fully Integrated 4D Cardiovascular Ultrasound System
  - GE Healthcare Debuts New Imaging System
  - New Discovery PET/CT Systems from GE Healthcare
  - SonoSite Presents SonoCalc IMT Software
  - Dade Behring Introduces High Sensitivity Troponin I Assay
  - Biosite Unveils New Diagnostic Test
  - MDS Diagnostic Services Unveils New Test to Prevent Heart Disease
  - diaDexus Develops PLAC Test
  - Siemens Introduces New Nuclear Cardiology Imaging System
  - Roche Diagnostics Receives U.S. Clearance and European CE Mark
  - Camtronics Unveils Cardiovascular Screening Software
  - Mayo Pioneers New Enzyme-Based Cardiovascular Risk Assessment Test
- 6.Recent Industry Activity
  - Siemens Medical acquires Dade Behring
  - Inverness Medical Innovations Acquires Cholestech
  - Acrongenomics, Pearson and Molecular Enter into Joint Venture
  - Cholestech Teams up with Onsite Health Diagnostics
  - Lipomics to Collaborate with Agilent Technologies to Develop Diagnostic Tests.
  - Transgenomic and Fiuotecnica Renew Collaboration Agreement
  - Alteon and BioRap Technologies Enter into an Agreement
  - IM Medical Acquires New Technology for Detecting Cardiovascular Diseases
  - Medtronic Establishes New Business Entity
  - Siemens Medical Acquires Bayer Healthcare's Diagnostics Unit
  - Spacelabs Acquires Ferraris' Cardiac Unit
  - Global Immune Takes over Primedical International
  - Siemens Acquires Diagnostics Products
  - Cholestech and Life Line Enter into Collaboration
  - LipoScience Signs an Agreement with ARUP
  - Philips Acquires Witt Biomedical
  - CardioDynamics Enters into an OEM Agreement with Shenzhen Mindray
  - Biosense Enters into Strategic Partnership with Siemens Medical Solutions
  - Dade Behring Approved the Use of FSAP Antibodies by American Diagnostica
  - Abbott Receives Non-exclusive Sublicense for Diagnostic Use of PIGF
  - Nanogen Acquires Spectral's Cardiac Test Division
  - Varian Enters into Alliance with LipoScience to Jointly Develop NMR System
  - Cardiac Services Professionals Establishes eCardio Diagnostics
  - Response Biomedical Wins Nonexclusive License Rights for NT-proBNP and Troponin T
  - Biomerieux gains Nonexclusive License for NT-proBNP
  - Philips and PMI Ink an Agreement for Outpatient Facility
  - LipoScience Enters into an Agreement with LabCorp
  - Abbott and Cleveland Clinic to Co-develop Myeloperoxidase Cardiac Test
  - Abbott Receives 510(k) Clearance from FDA for Myoglobin Test
  - FDA Clears Additional Claim for Biosite's Triage(R) BNP Test
  - Biosite Inks an Agreement with University of Mainz
  - Dade Behring Receives FDA Clearance for Advanced D-Dimer Assay
  - Nanogen Acquires SYNX Pharma
  - GE Takes over Amersham Plc
  - St. Jude Medical Acquires Irvine Biomedical and Epicor
  - SonoSite Snaps up SonoMetric
  - CardioDynamics Purchases Vermed
  - Philips and EP MedSystems Announce an Alliance Involving Electrophysiology Solutions
  - Toshiba and ViTAL Enters into an Alliance with Johns Hopkins University School of Medicine
  - Response Biomedical Collaborates with Shionogi
  - Terumo Signs Agreement with Spencer Technologies
  - Spectral Diagnostics Announces Agreement with NGC Medical
  - Philips Signs Agreement with Fletcher Allen Health Care
  - Spectral Diagnostics Enters into an Agreement with Cardinal Health
  - Siemens Signs Agreement with MediGuide
  - Biosite Enters into Agreement with DMI BioSciences
  - Cambridge Heart Enters into Agreement with Del Mar Reynolds
  - Cholestech Enters into an Agreement with Itamar Medical
  - Siemens Enters into a Contract with HiPGraphics
  - Abbott Announces US Clearance for Axis-Shield's BNP Test for Use on AxSYM
  - Cholestech Announces FDA 510(k) Approval for hs-CRP Test
  - Dade Behring Bags FDA Clearance NT-proBNP Test
  - Dade Behring Receives FDA Clearance for N High Sensitivity CRP Assay
  - EP-4 Computerized Cardiac Stimulator Bags FDA Approval
  - Biosite Adds two new offices
  - Bayer Diagnostics Enhances BNP Assay Offering Globally
  - EP MedSystems Garners CE Approval for ALERT Deflectable CS Catheter in Europe
  - Cambridge Heart Inc and Quinton Cardiology Systems Renew Pact
  - EPIX and Schering AG Extends Collaboration Agreement
  - Siemens Ultrasound and TomTec Imaging Systems Announces Agreement
  - FIT Biotech Plc Acquires Xenerate Ab to Develop Innovative Cardiovascular Devices
  - Beckman Coulter Enters into Agreement with Biosite
  - Dade Behring Garners Non-exclusive Rights for a Key Cardiac Marker
  - Bracco Diagnostics Inc., Joins Hand with Eastern Isotopes Inc to Develop CardioGen-82
  - New Lab Test from diaDexus Receives FDA Clearance
  - Hypertension Diagnostics Receives SDA Approval in China
- 7.Focus on Select Global Players
  - Abbott Diagnostics (USA)
  - Biosite Inc. (USA)
  - Cambridge Heart, Inc. (USA)
  - Cholestech Corp. (USA)
  - EP Medsystems (USA)
  - GE HealthCare (USA)
  - Liposcience, Inc. (USA)
  - Philips Medical Systems (USA)
  - Roche Diagnostics (Switzerland)
  - Siemens Medical Solutions (Germany)
- 8.Global Market Perspective
III. Market
- 1.The United States
  - A. Market Analysis
    - Startling Facts Related to Cardiovascular Disease in the US
    - Cardio Vascular Disease (CVD) - An Overview
    - Startling facts related to Stroke in US
    - Incidence of Coronary Heart Disease
    - Mortality rate of CHD
    - Arrhythmias
    - CAD Diagnostics
    - PVD Diagnostics
    - Medicare Reimbursement Set for CPT Code 83704
    - Competitive Glance
    - Point-of-Care (POC) Diagnostic Market in the US
    - Review of Major Players
    - Abbott Diagnostics
    - Biosite Inc
    - Cambridge Heart, Inc
    - Cholestech Corp
    - EP Medsystems
    - Liposcience, Inc.
    - Philips Medical Systems
    - Product Launches/Developments
    - Strategic Developments
  - B. Market Analytics
- 2.Canada
  - A. Market Analysis
    - Product Launch
    - Strategic Developments
  - B. Market Analytics
- 3.Japan
  - A. Market Analysis
    - Strategic Developments
  - B. Market Analytics
- 4.Europe
  - A. Market Analysis
    - European Union Cardiovascular Diseases Fact Sheet
    - in Vivo Diagnostics - Leading Segment
    - Germany - The Largest European Market
    - Product Launches
  - B. Market Analytics
- 4a.France
  - A. Market Analysis
    - Strategic Development
  - B. Market Analytics
- 4b.Germany
  - A. Market Analysis
    - Siemens Medical Solutions - A Major Player
    - Product Launches
    - Strategic Developments
  - B. Market Analytics
- 4c.Italy
  - A. Market Analysis
    - Strategic Developments.
  - B. Market Analytics
- 4d.The United Kingdom
  - A. Market Analysis
    - UK Cardiovascular Diseases Fact Sheet
    - Key Player Review
    - GE HealthCare
  - B. Market Analytics
- 4e.Spain
  - Market Analysis
- 4f.Russia
  - Market Analysis
- 4g.Rest of Europe
  - A. Market Analysis
    - Roche Diagnostics - A Key Swiss Player
  - B. Market Analytics
- 5.Asia Pacific
  - A. Market Analysis
    - Cardiovascular Market in Asia-Pacific
    - China
    - Cardiovascular Disease Patients Overview
    - Treatment Providers and Hospitals Overview
    - Hospitals
    - Chinese Cardiovascular Disease Treatment as a Part of Overall Health Care Industry
    - Strategic Developments
  - B. Market Analytics
- 6.The Middle East
  - Market Analysis
- 7.Latin America
  - A. Market Analysis
    - Strategic Development
  - B. Market Analytics
IV. Competitive Landscape
List of Tables
- Table 1: World Recent past, Current & Future Market Analysis for Cardiovascular Disease Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 2: World Long-term Projections for Cardiovascular Disease Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 3: World 10-Year Perspective for Cardiovascular Disease Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)
- Table 4: World Recent past, Current & Future Market Analysis for Cardiovascular in Vitro Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 5: World Long-term Projections for Cardiovascular in Vitro Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 6: World 10-Year Perspective for Cardiovascular in Vitro Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)
- Table 7: World Recent past, Current & Future Market Analysis for Cardiovascular in Vivo Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 8: World Long-term Projections for Cardiovascular in Vivo Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 9: World 10-Year Perspective for Cardiovascular in Vivo Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)
- Table 10: Prevalence of Cardiovascular Disease in the US in the Recent past (2004) (includes corresponding Graph/Chart)
- Table 11: Percentage Breakdown of Deaths from Cardiovascular Diseases in the USin the Recent past (2004) (includes corresponding Graph/Chart)
- Table 12: Prevalence of Cardiovascular Diseases among Americans by Age (Age 20 and Older) and Sex in the Recent past (2004) (includes corresponding Graph/Chart)
- Table 13: A Factoid of CHD and MI in the US in the Recent past (2003) (in Million)
- Table 14: A Factoid of Stroke in the US in the Recent past (2003) (in Million)
- Table 15: Annual Number of Americans Having Diagnosed Heart Attack by Age and Sex in the Recent past (2004) (includes corresponding Graph/Chart)
- Table 16: Prevalence of CHD by Age and Sex in the Recent past (2004) (in % population) (includes corresponding Graph/Chart)
- Table 17: Leading Players in the US POC Cardiac Market (2004) - Percentage Breakdown by Value Sales for Biosite, Dade Behring, Spectral Diagnostics, Roche and Others (includes corresponding Graph/Chart)
- Table 18: US Recent past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 19: US Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 20: US 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for in Vitro Diagnostics and in Vivo Diagnostics Markets for 2000, 2007 & 2010
- Table 21: Canadian Recent past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 22: Canadian Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 23: Canadian 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for in Vitro Diagnostics and in Vivo Diagnostics Markets for 2000, 2007 & 2010
- Table 24: Japanese Recent past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 25: Japanese Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 26: Japanese 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for in Vitro Diagnostics and in Vivo Diagnostics Markets for 2000, 2007 & 2010
- Table 27: European Recent past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 28: European Long-term Projections for Cardiovascular Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 29: European Recent past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 30: European Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 31: European 10-Year Perspective for Cardiovascular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart)
- Table 32: European 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for in Vitro Diagnostics and in Vivo Diagnostics Markets for 2000, 2007 & 2010
- Table 33: French Recent past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 34: French Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 35: French 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for in Vitro Diagnostics and in Vivo Diagnostics Markets for 2000, 2007 & 2010
- Table 36: German Recent past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 37: German Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 38: German 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for in Vitro Diagnostics and in Vivo Diagnostics Markets for 2000, 2007 & 2010
- Table 39: Italian Recent past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 40: Italian Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 41: Italian 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for in Vitro Diagnostics and in Vivo Diagnostics Markets for 2000, 2007 & 2010
- Table 42: UK Recent past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 43: UK Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 44: UK 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for in Vitro Diagnostics and in Vivo Diagnostics Markets for 2000, 2007 & 2010
- Table 45: Spanish Recent past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 46: Spanish Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 47: Spanish 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for in Vitro Diagnostics and in Vivo Diagnostics Markets for 2000, 2007 & 2010
- Table 48: Russian Recent past, Current & Future Analysis for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 49: Russian Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 50: Russian 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for in Vitro Diagnostics and in Vivo Diagnostics Markets for 2000, 2007 & 2010
- Table 51: Rest of Europe Market for Cardiovascular Disease Diagnostics - Recent past, Current & Future Market Analysis by Product Segment for in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 52: Rest of Europe Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 53: Rest of Europe 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for in Vitro Diagnostics and in Vivo Diagnostics Markets for 2000, 2007 & 2010
- Table 54: Cardiovascular Special Treatment Hospitals in China: 1991-2011(in numbers) (includes corresponding Graph/Chart)
- Table 55: Cardiovascular Diseases Treatment inChina: 1991-2011(in US$ million) (includes corresponding Graph/Chart)
- Table 56: Asia-Pacific Market for Cardiovascular Disease Diagnostics - Recent past, Current & Future Market Analysis by Product Segment for in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 57: Asia-Pacific Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 58: Asia-Pacific 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for in Vitro Diagnostics and in Vivo Diagnostics Markets for 2000, 2007 & 2010
- Table 59: Middle East Market for Cardiovascular Disease Diagnostics - Recent past, Current & Future Market Analysis by Product Segment for in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 60: Middle East Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 61: Middle East 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for in Vitro Diagnostics and in Vivo Diagnostics Markets for 2000, 2007 & 2010
- Table 62: Latin American Market for Cardiovascular Disease Diagnostics - Recent past, Current & Future Market Analysis by Product Segment for in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 63: Middle East Long-term Projections for Cardiovascular Disease Diagnostics by Product Segment - in Vitro Diagnostics and in Vivo Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 64: Latin American 10-Year Perspective for Cardiovascular Disease Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for in Vitro Diagnostics and in Vivo Diagnostics Markets for 2000, 2007 & 2010